The predecessor of NeuroCure, PREP lab, worked close to 15 years with PREP and its functions on neurodegenerative diseases, and the PREP ligand development project, a fruitful collaboration between Prof. Timo Myöhänen and Dr. Erik Wallén, has also been active for 10 years. Now the PREP ligands have taken a further step in the drug development process, as Polku Therapeutics was founded with the funding acquired from Innovester (Helsinki, Finland) and Torrey Pines Investment (San Diego, USA). The goal for Polku is to continue the development of PREP ligands towards the clinical trials of neurodegenerative diseases, such as Parkinson's disease and Tauopathies.
"This was the best thing that could happen for the PREP ligand development, as the academic possibilities to further develop PREP ligands were basically over. I'm super excited to see how far in the drug development our ligands and ideas can reach, and of course hope to see them helping patients in the future", comments Prof. Timo Myöhänen, the co-founder and scientific advisor of Polku Therapeutics.
More information can be found here: